The FDA has approved Novavax's Nuvaxovid, a non-mRNA COVID vaccine aimed at adults 65 and high-risk individuals aged 12-64. Although the approval is limited, many people qualify due to underlying conditions. Nuvaxovid offers an effective alternative, with simpler storage and fewer side effects compared to other vaccines.
